Stromelysin-3 (ST-3): Immunohistochemical characterization of the matrix metalloproteinase (MMP)-11 in benign and malignant skin tumours and other skin disorders

Clinical and Experimental Dermatology

Volumn 24, Issue 2, 1999, Pages 122-126

  Thewes, M ^a   Worret, W I ^b   Engst, R ^b   Ring, J ^b  

^a Praxis/Lab of Dermatohistopathology   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX METALLOPROTEINASE; MONOCLONAL ANTIBODY; SCLEROPROTEIN; STROMELYSIN;

ARTICLE; BASAL CELL CARCINOMA; CONTROLLED STUDY; DERMATOFIBROMA; DERMATOFIBROSARCOMA PROTUBERANS; EXTRACELLULAR MATRIX; FIBROXANTHOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALIGNANT FIBROUS HISTIOCYTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN CANCER; SKIN DISEASE; SKIN FIBROBLAST; SKIN TUMOR; SQUAMOUS CELL CARCINOMA;

CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; FIBROBLASTS; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 11; MELANOMA; METALLOENDOPEPTIDASES; SKIN; SKIN DISEASES; SKIN NEOPLASMS;

EID: 0032931194     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2230.1999.00431.x     Document Type: Article

References (25)

1. 1 Matrisian LM. Metalloproteinases and their inhibitors in matrix modelling. Trends Genet 1990; 6: 121-5.
2. 2 Matrisian LM. The matrix-degrading metalloproteinases. Bio Essays 1992; 14: 455-63.
3. 3 Nakajima M, Chop AM. Tumor invasion and extracellular matrix degradative enzymes: regulation of activity by organ factors. Cancer Biol 1991; 2: 115-27.
4. 4 Heppner KJ, Matrisian LM, Jensen RA, Rodgers WH. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol 1996; 149: 273-82.
5. 5 Anglard P, Melot T, Guerin E et al. Structure and promoter characterization of the human stromelysin-3 gene. J Biol Chem 1995; 270: 20337-44.
6. 6 Basset P, Bellocq JP, Wolf C et al. A novel metalloproteinases gene specifically expressed in stromal cells of breast carcinomas. Nature 1990; 348: 699-704.
7. 7 Birkedal-Hansen H. Proceedings of the Matrix Metalloproteinase Conference. Destin, FL:.Gustav Fischer-Verlag, 1992.
8. 8 Levy A, Zucman J, Delattre O et al. Assignment of the human stromelysin 3 (STMY 3) gene to the q1 1.2 region of chromosome 22. Genomcs 1992; 13: 881-3.
9. 9 Anderson IC, Sugarbaker DJ, Ganju RK et al. Stromelysin-3 is overexpressed by stromal elements in primary non-small cell cancers and regulated by retinoic acid in pulmonary fibroblasts. Cancer Res 1995; 55; 4120-6.
10. 10 Urbanski SJ, Edwards DR, Maitland A et al. Expression of metalloproteinases and their inhibitors in primary pulmonary carcinomas. Br J Cancer 1992; 66: 1188-94.
11. 11 Rouyer N, Wolf C, Chenard MP et al. Stromelysin-3 gene expression in human cancer: an overview. Invasion Metastasis 1994; 14: 269-75.
12. 12 Wolf C, Rouyer N, Lutz Y et al. Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possible implicated in tumor progression. Proc Natl Acad Sci, USA 1993; 90: 1843-7.
13. 13 Thewes M. Pohlmann G, Atkinson M et al. Stromelysin-3 (ST-3) mRNA expression in colorectal carcinomas, localization and clinicopathologic correlations, Diag Mol Pathol 1996; 5: 284-90.
14. 14 Basset P, Wolf C, Chambon P. Expression of the stromelysin-3 gene in fibroblastic cells of invasive carcinomas of the breast and other human tissues: a review. Breast Cancer Res Treat 1993; 24: 185-93.
15. 15 Basset P, Wolf C, Rouyer N et al. Stromelysin-3 in stromal tissue as a control factor in breast cancer behavior. Cancer 1994; 74 (Suppl.): 1045-9.
16. 16 Kossakowska AE, Huchcroft SA, Urbanski SJ. Edwards DR. Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin's lymphomas in humans, Br J Cancer 1996; 73: 1401-8.
17. 17 Majmudar G, Nelson BR, Jensen TC et al. Increased expression of stromelysin-3 in basal carcinomas. Mol Carcinogen 1994; 9: 17-23.
18. 18 Wagner SN, Ruhri C, Kunth K et al. Expression of stromelysin 3 in the stromal elements of the human basal cell carcinoma. Diag Mol Path 1992; 3: 200-5.
19. 19 Wolf C, Chenard MP, Durand de Grossouvre P et al. Breast-cancer-associated stromelysin-3 gene is expressed in basal cell carcinoma and during cutaneous wound healing. J Invest Dermatol 1992; 99: 870-2.
20. 20 Lefebvre O, Regnier C, Chenard MP et al. Developmental expression of mouse stromelysin-3 mRNA. Development 1995; 121: 947-55.
21. 21 Santavicci M, Noel A, Chenard MP et al. Characterization of monoclonal antibodies against stromelysin-3 and their use to evaluate stromelysin-3 levels in breast carcinoma by semi-quantitative immunohistochemistry. Int J Cancer 1995; 64: 336-41.
22. 22 Cordell JL, Falini B, Erber WN et al. Immunencymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase anti-alkaline phosphatase (APAAP). J Histochem Cytochem 1984; 32; 219-29.
23. 23 Unden AB, Sandstedt B, Bruce K et al. Stromelysin-3 mRNA associated with myofibroblasts is overexpressed in aggressive basal cell carcinoma and in dermatofibroma but not in dermatofibrosarcoma. J Invest Dermatol 1996; 107: 147-53.
24. 24 Calonje E, Fletcher CDM. Cutaneous fibrohistiocytic tumors: an update. Adv Anat Pathol 1994; 1: 2.
25. 25 Nawrocki B, Polette M, Clavel C et al. Expression of stromelysin-3 and tissue inhibitors of matrix. Pathol Res Pract 1994; 190: 690-6.